We invite EONS members who missed out on our September 2014 Congress to catch up on the highlights using the video resources on this page.
Xofigo satellite symposium
This symposium was entitled Focus on Metastatic CRPC Patients With Bone Metastases: Integrating Radium-223 Into Patient Management. It was sponsored by Bayer HealthCare, which has developed radium-223 under the trade name Xofigo.
A panel of nurse experts addresses challenges in cancer management, as well as the unique role that nurses play in coordinating care with patients and the multidisciplinary healthcare team.
This symposium is a chance to learn more about radium-223/Xofigo as a treatment option. It also provides useful advice on how to maintain dialogue with patients before, during and after treatment for castration-resistant prostate cancer.